The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-31. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
A smart insulin patch, also known as a glucose-responsive insulin patch, is a type of wearable medical device for diabetes treatment. It is a transdermal patch comprising glucose-sensitive microneedle-array loaded with insulin for blood glucose regulation. Once applied on the skin, the microneedles penetrate under the skin and can sense blood sugar levels. If glucose levels go up, it can promote the release of insulin, which is transported through the regional lymph and capillary vessels for glucose regulation.
=== Metalloproteomics === Sarkar, along with his colleague Eve Roberts, a hepatologist and Wilson's disease specialist, pioneered the development of metalloproteomics. He first presented its concept and findings relating to copper in 2002.
== Genetics == Several genes have been implicated in the etiology of Walker–Warburg syndrome, and following genes are: POMT1, POMT2, POMGNT1, FKTN, FKRP, LARGE, CRPPA, GTDC2, DAG1, RXYLT1, B3GALNT2, POMK, B3GNT1, GMPPB. All these enzymes (except for DAG1, which is dystroglycan itself) participate in glycosylation of α-dystroglycan, which is important for the proper function of the protein. DAG1 mutations can cause either hypoglycosalation or pertubated maturation/transport to plasma membrane. First gene to cause WWS, POMT1, was discovered in 2001 by de Bernabe and colleagues.
Sources: en.wikipedia.org
The first known evidence of people in the district comes from an archaeological site in Fenwood Heights, which has been dated to 8000 BCE. The site contains the remains of a camp of nomadic hunters and foragers, and there is no evidence of permanent settlers. In the 17th century, the area was inhabited by the Seneca at the village of Ganatsekwyagon. They were later displaced by the Mississaugas, who were themselves displaced by the European settlers who began to arrive in the late 18th century. After the land was surveyed in 1793, it was opened to settlement by British subjects with the first issue of land patents in 1796, although squatters had already been present for a few years. The first settlers were David and Andrew Thomson. They were stonemasons who worked on the first parliament buildings for York. They each built mills. This activity led to the creation of a small village known as the Thomson Settlement. The first post office opened in 1832, in Scarborough Village. During the early part of life in Upper Canada, local administration and justice was administered by the colonial government. From 1792 to 1841, magistrates were appointed by District Councils. There were four districts in the colony of which Scarborough was part of the Home District. Partly due to a political reorganization that was a result of the Durham Report, Scarborough gained elected representation on the Home District Council. Scarborough elected two councillors. In 1850, the district was incorporated as a township.
With Prussia on the verge of official dissolution (1947), Hanoverian politicians in 1946 took advantage of the opportunity and advocated that the Control Commission for Germany (British Element) (CCG/BE) revive Hanoverian statehood, reconstituting the Prussian Province of Hanover as the State of Hanover. The state saw itself in the tradition of the kingdom. Its prime minister, Hinrich Wilhelm Kopf, played a central role when the state of Lower Saxony was founded just a few months later by merging Hanover with several smaller states, with the city of Hanover as its capital. The former territory of Hanover makes up 85 per cent of Lower Saxony and is the origin of its coat of arms.
Phosphorus pentachloride: SO2 + PCl5 → SOCl2 + POCl3 Chlorine and sulfur dichloride: SO2 + Cl2 + SCl2 → 2 SOCl2 SO3 + Cl2 + 2SCl2 → 3 SOCl2 Phosgene: SO2 + COCl2 → SOCl2 + CO2 The second of the above five reactions also affords phosphorus oxychloride (phosphoryl chloride), which resembles thionyl chloride in many of its reactions. They may be separated by distillation, since thionyl chloride boils at a much lower temperature than phosphoryl chloride.
According to the European Union Drugs Agency, the estimated minimum lethal dose is 1.2 grams. However, sensitive individuals have died from as little as 30 milligrams applied to mucous membranes-an amount that is 40 times less than the minimum lethal dose. In contrast, addicts may tolerate doses as high as 5 grams per day. Use of cocaine causes abnormally fast heart rhythms and a marked elevation of blood pressure (hypertension), which can be life-threatening. This can lead to death from acute myocardial infarction, acute respiratory failure (i.e., hypoxemia, with or without hypercapnia), stroke, cerebral hemorrhage, and sudden cardiac arrest. Overdose can also cause acute hepatotoxicity—typically due to toxic metabolites—though most cases resolve quickly; however, fatal outcomes from multiple organ dysfunction syndrome are possible, and there is no specific antidote. Cocaine overdose may result in hyperthermia as stimulation and increased muscular activity cause greater heat production. Heat loss is also inhibited by the cocaine-induced vasoconstriction. In 2024, drug-related deaths in England and Wales reached their highest level in three decades, with a notable increase in fatalities involving cocaine and experts urging urgent government intervention to address the crisis. Martin Powell, from the charity Transform, which campaigns for the legal regulation of drugs, suggested that the recent rise in cocaine-related deaths in the UK may be due to the increased purity of cocaine, leading users to consume it more frequently and alongside other substances.
Sources: en.wikipedia.org
Beta blockers act as β-adrenergic receptor antagonists. They may be non-selective, antagonizing both the β1- and β2-adrenergic receptors, or they may be selective for antagonism of the β1-adrenergic receptor (often referred to as "cardioselective"). Some beta blockers have intrinsic sympathomimetic activity (ISA), otherwise known as partial agonist activity at the β-adrenergic receptors with weak sympathomimetic effects. Some beta blockers are not selective for the β-adrenergic receptor and have additional α1-adrenergic receptor antagonism. Some beta blockers have membrane-stabilizing activity, otherwise known as sodium channel blockade or local anesthetic activity. Beta blockers vary in their lipophilicity versus hydrophilicity and hence in their capacity to cross the blood–brain barrier, with some having central nervous system effects and others being peripherally selective.
It is produced by the bacterium Streptomyces hygroscopicus and was isolated for the first time in 1972, from samples of S. hygroscopicus found on Easter Island. The compound was originally named rapamycin after the native name of the island, Rapa Nui. Sirolimus was initially developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties due to its ability to inhibit mTOR. It was approved by the US Food and Drug Administration (FDA) in 1999. Hyftor (sirolimus gel) was authorized for topical treatment of facial angiofibroma in the European Union in May 2023.
Coffin separation: the body is placed into the chamber. Cryogenic freezing: liquid nitrogen at −196 °C crystallizes the body. Vibration: the body is disintegrated into particles. Freeze drying: particles are freeze dried in a drying chamber, leaving approximately 30% of the original weight. Metal separation: any metals (e.g., tooth amalgam, artificial hips, etc.) are removed, either by magnetism or by sieving. The dry powder is placed in a biodegradable casket which is interred in the top layers of soil, where aerobic bacteria decompose the remains into humus in as little as 6–12 months.
Flavin reductase is a dimer made up of two subunits. Each subunit is similar. Flavin reductase P, FRP, was studied by Tanner, Lei, Tu and Krause and was discovered to have a structure made up of two subunits each containing a sandwich domain and an excursion domain. The excursion domains of each subunit reach out to connect the sandwich domain of the other subunit. This creates a large hydrophobic core in flavin reductase The enzyme has two binding sites, one for NADPH and one for the flavin mononucleotide substrate. The isoalloxazine ring of flavin mononucleotide is where reduction occurs. Therefore, this is where flavin creates a variety of hydrogen bonds to connect to the amino acid side chains of flavin reductase. Side chains 167–169 in FRP block the isoalloxazine ring in FAD from binding the enzyme, making FRP an FMN specific flavin reductase. The placement of methyl groups in the isoalloxazine ring can also have an effect on the binding and specificity of the enzyme for substrate. There is a depletion of a C-terminal extension that allows for the binding of NADPH, and studies show that if it is removed, it is depleted, catalytic activity increases.
=== Anne Marie West === In September 1972, the Wests led eight-year-old Anne Marie to the cellar at 25 Cromwell Street. The child was ordered to undress, with Rose tearing her dress from her body upon noting the child's hesitation. She was then stripped naked, bound to a mattress and gagged before Fred raped her with Rose's active encouragement. After the rape, Rose followed Anna Marie to the bathroom and handed her a sanitary towel, explaining to the child, "Everybody does it to every girl. It's a father's job. Don't worry, and don't say anything to anybody." Making clear these sexual assaults would continue, Fred and Rose then threatened the child with severe beatings if they ever received word she had divulged the sexual abuse she endured at their hands. Rose occasionally sexually abused Anne Marie herself, and later took extreme gratification in degrading her with acts such as binding her to various items of furniture before encouraging Fred to rape her, or forcing her to perform household chores while wearing sexual devices and a miniskirt. Fred and Rose forced Anne Marie into prostitution from the age of 13, telling clients she was aged 16. Rose was always present in the room when these acts occurred to ensure the girl did not reveal her true age. On one occasion when Anne Marie was aged 13 or 14, Rose took her to a local pub, insisting she drink several glasses of barley wine. Several hours later, Fred arrived at the pub to collect Rose and Anne Marie.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.